IMI2 - Call 21 | Science|Business

Development of antivirals as well as other types of therapeutics to address a rapid response to the current COVID-19 outbreak; therapeutics to address the current and/or future coronavirus outbreaks; diagnostics, ensuring rapid evaluation of candidates based on existing technologies;
fast and reliable tools that go beyond the state of the art for detection of COVID-19 carriers and symptomatic individuals suspected of COVID-19 infection.

Amount

€45M

Agency or Funder

IMI

Eligibility (if available)

See funding call for eligibility rules

Keywords

Therapeutics

Drug Development

Diagnostics

Country

Link(s) to announcement or call